Astra Pharma (T) Ltd

Astra Pharma (T) Ltd is a prominent pharmaceutical importer and wholesaler based in Dar es Salaam, Tanzania. Established in 2002 as part of the Astra Group, the company has significantly contributed to the Tanzanian healthcare sector by providing quality pharmaceutical products. The Astra Group, founded in 1996, has a longstanding presence in East Africa, with operations in both Uganda and Tanzania.

The company operates as a primary wholesaler, sourcing a diverse range of pharmaceutical formulations from international suppliers, particularly from India. Astra Pharma (T) Ltd plays a crucial role in the distribution network, ensuring the availability of essential medications across Tanzania. Their extensive distribution network and partnerships with multinational companies underscore their commitment to enhancing healthcare access in the region.

Astra Pharma (T) Ltd's distribution network is centered in Dar es Salaam, the commercial hub of Tanzania. The company's headquarters are located at Block 6, House 35, Uhuru/Congo Street, Kariakoo, P.O. Box No. 38388, Dar es Salaam. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the strategic positioning in Dar es Salaam suggests a focus on efficient distribution throughout Tanzania. The company's partnerships with reputable multinational pharmaceutical companies further enhance its logistics capabilities, ensuring a steady supply of quality medications to meet the country's healthcare needs.

Astra Pharma (T) Ltd serves as a primary wholesaler in Tanzania's pharmaceutical supply chain. By importing a wide array of pharmaceutical formulations, the company acts as a critical intermediary between international manufacturers and local healthcare providers. This role is vital in ensuring the consistent availability of essential medications across the country, thereby supporting the overall healthcare infrastructure. The company's extensive distribution network and partnerships with multinational companies underscore its significant position in the Tanzanian pharmaceutical market.

Astra Pharma (T) Ltd's sourcing strategy exhibits a high degree of concentration, with a total import value of $931,000 USD from India across 26 shipments. The top five products imported are Clarithromycin ($900,000, 0.9% share) and Tofacitinib ($31,000, 0.8% share), indicating a focused product portfolio. This concentration suggests a strategic choice to streamline operations and maintain strong supplier relationships. However, such dependency on a limited number of suppliers and products could pose risks, including supply chain disruptions or market fluctuations affecting these specific products. The shipment data reveals a stable relationship with Indian suppliers, as evidenced by the consistent import volumes over the years. Nonetheless, diversifying the supplier base and product range could enhance resilience against potential supply chain challenges.

Astra Pharma (T) Ltd's supply chain resilience is closely tied to its partnerships with Indian suppliers, notably AJANTA PHARMA LIMITED, CENTAUR PHARMACEUTICALS PRIVATE LIMITED, and UNICHEM LABORATORIES LIMITED. The company's importation of finished pharmaceutical formulations, rather than raw APIs or bulk drugs, indicates a focus on ready-to-market products. While this approach simplifies logistics and regulatory compliance, it also means that Astra Pharma (T) Ltd is highly dependent on the stability and reliability of its Indian suppliers. The absence of publicly available information on backup suppliers and the company's overall formulation diversity suggests potential vulnerabilities in the supply chain. To enhance resilience, Astra Pharma (T) Ltd could consider diversifying its supplier base and exploring alternative sourcing options.

Astra Pharma (T) Ltd's concentrated sourcing pattern positions it as a key player in the Tanzanian pharmaceutical market, particularly in the antibiotic and advanced oncology therapeutic categories. This focus allows the company to leverage strong supplier relationships and maintain a streamlined product portfolio. For Indian exporters, this presents an opportunity to strengthen existing partnerships and explore avenues for introducing additional products within these therapeutic areas. However, the company's reliance on a limited number of suppliers and products also highlights the importance of ensuring consistent product quality and supply reliability to maintain its competitive position.

The Tanzania Medicines and Medical Devices Authority (TMDA) is the primary regulatory body overseeing the importation and exportation of pharmaceutical products in Tanzania. Established under the Tanzania Medicines and Medical Devices Act Cap. 219, TMDA is responsible for ensuring the safety, efficacy, and quality of medicines and medical devices in the country. The Act provides TMDA with the mandate to regulate the importation and exportation of medicines, medical devices, in vitro diagnostics, and biocidals. (tmda.go.tz)

Key legislation governing pharmaceutical imports includes the Pharmaceutical and Poisons Act and the Pharmaceutical and Poisons Regulations, which outline the control of manufacture, sales, import, and export of pharmaceutical products. The marketing authorization pathway for Indian generics involves obtaining import permits from TMDA, ensuring compliance with the regulatory standards set forth by the authority.

Import licensing requirements in Tanzania stipulate that all pharmaceutical products to be imported must be registered by TMDA unless given special approval by the Authority. Importers must register their premises with TMDA before applying for import permits. Applications for import permits must be submitted at least six weeks prior to loading the consignment to avoid storage costs at ports of entry and disposal costs of unpermitted products. (tmda.go.tz)

Regarding Good Manufacturing Practice (GMP) certification, TMDA recognizes certifications from facilities that comply with international standards, including EU GMP, WHO GMP, and PIC/S. Importers must ensure that the pharmaceutical products they import are manufactured in facilities holding such recognized certifications. Additionally, importers must obtain wholesale distribution authorization from TMDA, which involves meeting specific regulatory requirements and maintaining compliance with the Authority's guidelines.

Imported pharmaceutical products must undergo batch testing to ensure they meet the required quality standards set by TMDA. Stability requirements are enforced to guarantee that products remain effective and safe throughout their shelf life. Labeling language requirements mandate that product labels be in English and Kiswahili, the official languages of Tanzania, to ensure clear communication with consumers and healthcare providers. Serialization mandates are implemented to enhance traceability and prevent counterfeit products from entering the market, thereby safeguarding public health.

Between 2024 and 2026, TMDA has implemented several policy changes affecting pharmaceutical imports into Tanzania. These include stricter enforcement of import permit requirements, enhanced scrutiny of GMP certifications, and the introduction of more rigorous batch testing protocols. Additionally, TMDA has updated labeling and serialization mandates to align with international standards and improve product traceability. These regulatory changes aim to strengthen the quality assurance framework and ensure the safety and efficacy of pharmaceutical products in the Tanzanian market.

Astra Pharma (T) Ltd's product strategy focuses on importing finished pharmaceutical formulations, particularly in the antibiotic and advanced oncology therapeutic categories. This focus aligns with the company's objective to provide essential medications that address prevalent health concerns in Tanzania. The market demand for these products is driven by the high incidence of infectious diseases and cancer in the region, necessitating a reliable supply of effective treatments. By concentrating on these therapeutic areas, Astra Pharma (T) Ltd aims to meet critical healthcare needs and strengthen its position in the Tanzanian pharmaceutical market.

Astra Pharma (T) Ltd's sourcing strategy is centered on importing generic drugs from India, leveraging the country's robust pharmaceutical manufacturing sector. The company's preference for finished formulations indicates a focus on ready-to-market products, which simplifies logistics and regulatory compliance. India's compliance with international GMP standards, including EU GMP, WHO GMP, and PIC/S, aligns with TMDA's regulatory requirements, facilitating smoother import processes. This sourcing approach enables Astra Pharma (T) Ltd to offer a diverse range of quality medications to the Tanzanian market.

Based on its product mix, Astra Pharma (T) Ltd primarily serves the wholesale distribution segment of the Tanzanian pharmaceutical market. By importing and distributing a focused range of pharmaceutical formulations, the company acts as a critical intermediary between international manufacturers and local healthcare providers. This positioning allows Astra Pharma (T) Ltd to ensure the consistent availability of essential medications across the country, thereby supporting the overall healthcare infrastructure.

There is a realistic opportunity for new Indian suppliers to collaborate with Astra Pharma (T) Ltd, particularly in the antibiotic and advanced oncology therapeutic categories. The company's concentrated sourcing pattern indicates a potential openness to expanding its supplier base within these areas. Identifying gaps in Astra Pharma (T) Ltd's current sourcing, such as the need for additional product formulations or alternative suppliers, could present avenues for new suppliers to enter the market.